We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $49.39, moving -1.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%. Elsewhere, the Dow lost 1.24%, while the tech-heavy Nasdaq lost 0.21%.
Shares of the company have depreciated by 10.25% over the course of the past month, underperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company's upcoming EPS is projected at -$1.07, signifying a 8.55% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.95 million, up 1017.42% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$4.48 per share and a revenue of $32.45 million, demonstrating changes of +30.76% and +824.53%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 2.14% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $49.39, moving -1.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%. Elsewhere, the Dow lost 1.24%, while the tech-heavy Nasdaq lost 0.21%.
Shares of the company have depreciated by 10.25% over the course of the past month, underperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company's upcoming EPS is projected at -$1.07, signifying a 8.55% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $9.95 million, up 1017.42% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$4.48 per share and a revenue of $32.45 million, demonstrating changes of +30.76% and +824.53%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 2.14% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.